Lipocine Q1 net loss $1.9M; starts Phase 3 for PPD drug LPCN 1154

Lipocine Inc.

2025-Q1 EPS reported -$0.35 revenue$93,864

Net loss $1.9M ($0.35 diluted share) vs net income $3.5M ($0.66) in Q1 2024.
Cash and equivalents $19.7M at March 31, 2025, down from $21.6M at Dec 31, 2024.
Initiated outpatient Phase 3 study of LPCN 1154 (oral brexanolone) for postpartum depression; first patient dosing expected Q2 2025.
Entered TLANDO license agreement for Brazil with Aché; exploring partnerships for LPCN 1154 and LPCN 2401.
Plans proof-of-concept study for LPCN 2401 as adjunct to GLP-1 therapies, targeting elderly patients.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.